THE ROBERT H. LURIE COMPREHENSIVE CANCER CENTER and the Northwestern Medicine Developmental Therapeutics Institute entered into an alliance with Perthera Inc. to conduct a translational research program designed to assess the utility of integration of next generation sequencing, proteomic, and phospho-proteomic data in oncology developmental therapeutics and clinical practice.
The Lurie Cancer Center and NMDTI will work with Perthera on clinical protocols that incorporate Perthera’s approaches and methodologies to cancer protocol treatment and will assess the impact on overall disease management and patient outcomes.
Separately, in June, Perthera announced a partnership with the Pancreatic Cancer Action Network to identify relevant pathways and mutations for pancreatic cancer, including previously unidentified targets.
